Clinical Investigations Adjuvant high dose rate brachytherapy for soft tissue sarcomas: initial experience report

Bradley, Julie A.; Kleinman, Sara H.; Rownd, Jason; King, David M.; Hackbarth, Donald A.; Whitfield, Robert; Wang, Dian

doi:10.5114/jcb.2011.21036

Cited by 5 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study and further studies have indicated that brachytherapy has no impact on local control for low grade soft tissue sarcomas. If brachytherapy is used, the dose is 40-45 Gy to a volume that includes all margins; when it's used as a boost in combination with externalbeam irradiation, a dose of 20-25 Gy is utilized [30]. In a study conducted at Memorial Sloan-Kettering Cancer Center (MSKCC), over a 15-year period, 202 patients with high-grade sarcoma of the extremities were treated with complete gross resection followed by brachytherapy delivered over 5 days, with a median dose of 45 Gy.…”

Section: Discussionmentioning

confidence: 99%

Soft Tissue Sarcomas: Epidemiological, Clinical and Therapeutic Aspects

Raouah¹,

Agouzzal²,

Darfaoui³

et al. 2023

EAS J Orthop Physiother

View full text Add to dashboard Cite

Soft-tissue sarcomas (STS) are a rare, and comprise a relatively heterogeneous group of malignant tumors arising from mesenchymal tissue. STS can affect any age group. In order to provide patients suffering from STS, with a functional extremity without local tumor relapse, treatment decisions must involve a multidisciplinary team decision-making approach. We conducted a retrospective, descriptive study, of 43 cases of soft tissue sarcoma, collected between January 2013 and December 2018, in the department of Radiation-Oncology of the Oncology and hematology hospital of Mohammed VI University Teaching Hospital. With this study we aimed to report the epidemiological, clinical, histological, therapeutic and evolutionary characteristics of soft tissue sarcomas in the Radiation-Oncology department, and to define the factors influencing patient survival in order to improve the quality of care. The items collected were: epidemiological, clinical, histological, radiological, and therapeutic. Univariate and then multivariate analyzes were performed looking for factors influencing 2-year survival. During the study period, we collected 43 cases, 22 Men and 21 Women, the average age was 45.23 years (Extreme = 11-78 years). The tumor was deep in 73% percent of the cases, and the lower limbs were the most affected (65%) especially in the thigh. The predominant histological type was Liposarcoma in 16 cases (37.20%). The tumor stage was localized in 35 cases (81.39%), metastatic in 8 cases (18.60%). Thirty-five tumors were treated with surgery, including 31 cases (88.57%) of conservative surgery and 4 cases (11.42%) of radical surgery. Radiotherapy was performed in 33 patients, and chemotherapy in 24 patients. Follow-up monitoring has detected 5 cases (28%) of local recurrence, and 13 other cases (72%) of distant metastases. In univariate analysis the prognostic factors were age (p = 0.03) and tumor stage (p = 0.09). In our study, radiation therapy is an integral part of the ......

show abstract

Section: Discussionmentioning

confidence: 99%

Soft Tissue Sarcomas: Epidemiological, Clinical and Therapeutic Aspects

Raouah¹,

Agouzzal²,

Darfaoui³

et al. 2023

EAS J Orthop Physiother

View full text Add to dashboard Cite

show abstract

“…The place of brachytherapy as monotherapy is only valuable in low-risk situations or in case re-irradiation can be considered afterwards (15). If applied as a booster to adjuvant RT, brachytherapy is described to give excellent local control and limited toxic complications (18). However toxic side effects have been described (13,15).…”

Section: Discussionmentioning

confidence: 99%

Intraoperative Brachytherapy Combined With Adjuvant Radiotherapy Shows Equal Results in the Treatment of Leiomyosarcoma on the Extremities Compared to Adjuvant Radiotherapy Only – A Multicentric Retrospective Analysis

et al. 2022

View full text Add to dashboard Cite

Background/Aim: Leiomyosarcomas account for 2-10% of all extremity soft tissue sarcomas. The role of intraoperative brachytherapy as an additive booster therapy is not clearly defined. This study focused on the additive value of brachytherapy in the treatment of leiomyosarcomas on the extremities. Patients and Methods: This retrospective multicenter study compared treatment outcomes of 94 patients diagnosed with a primary leiomyosarcoma in their extremities. Patients were divided into three groups according to their radiotherapy protocol: a) adjuvant radiotherapy (aRT), b) neoadjuvant radiotherapy (nRT) and c) intraoperative brachytherapy combined with adjuvant radiotherapy (IOBTaRT). These three treatment groups were compared for local control, time to metastasis, and overall survival. Results: Eleven patients were treated with IOBTaRT, 35 patients with aRT, and seven patients with nRT only. The survival time was 157.6 months for patients in the IORTaRT group, and 111.3 months for patients treated with aRT only. The time to local recurrence was 141.5 months for patients treated with IOBTaRT and 106.1 months for patients treated with aRT. The estimated time to metastasis was 34.6 months for patients in the IOBTaRT group and 69.7 months for patients treated with aRT alone. No significant differences were observed between these treatment groups concerning overall survival, local recurrence, or metastasis. Conclusion: Additive brachytherapy did not provide a significant advantage in the treatment of leiomyosarcomas. However, this study was limited by the number of patients per group.

show abstract

“…A study was performed in eight patients with unresectable pancreatic head tumors, suffering from pain of high intensity who were candidates for palliative surgery due to jaundice and/or recurrent ileus ( 56 ). They underwent perioperative high dose rate brachytherapy with 192 Iridium implants.…”

Section: Applications In Pancreatic Cancer Therapymentioning

confidence: 99%

“…The patients who underwent perioperative palliative brachytherapy described more pain relief. Mean survival time was 6.7 months in the brachytherapy group, vs. 4.4 months in the group where no brachytherapy was performed ( 56 ).…”

Section: Applications In Pancreatic Cancer Therapymentioning

confidence: 99%

New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review

et al. 2021

View full text Add to dashboard Cite

The use of radioactivity in medicine has been developed over a century. The discovery of radioisotopes and their interactions with living cells and tissue has led to the emergence of new diagnostic and therapeutic modalities. The CERN-MEDICIS infrastructure, recently inaugurated at the European Center for Nuclear Research (CERN), provides a wide range of radioisotopes of interest for diagnosis and treatment in oncology. Our objective is to draw attention to the progress made in nuclear medicine in collaboration with CERN and potential future applications, in particular for the treatment of aggressive tumors such as pancreatic adenocarcinoma, through an extensive review of literature. Fifty seven out of two hundred and ten articles, published between 1997 and 2020, were selected based on relevancy. Meetings were held with a multi-disciplinary team, including specialists in physics, biological engineering, chemistry, oncology and surgery, all actively involved in the CERN-MEDICIS project. In summary, new diagnostic, and therapeutic modalities are emerging for the treatment of pancreatic adenocarcinoma. Targeted radiotherapy or brachytherapy could be combined with existing therapies to improve the quality of life and survival of these patients. Many studies are still in the pre-clinical stage but open new paths for patients with poor prognosis.

show abstract

Clinical Investigations Adjuvant high dose rate brachytherapy for soft tissue sarcomas: initial experience report

Cited by 5 publications

References 23 publications

Soft Tissue Sarcomas: Epidemiological, Clinical and Therapeutic Aspects

Soft Tissue Sarcomas: Epidemiological, Clinical and Therapeutic Aspects

Intraoperative Brachytherapy Combined With Adjuvant Radiotherapy Shows Equal Results in the Treatment of Leiomyosarcoma on the Extremities Compared to Adjuvant Radiotherapy Only – A Multicentric Retrospective Analysis

New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review

Contact Info

Product

Resources

About